Articles > Popular publications > PR Newswire press releases > January-March 2004 > Wednesday, March 24

Article: QRxPharma and Shire Laboratories Collaborate on a Novel Controlled Release Opioid Product; Immediate Release Formulation of Novel Opioid is Ready to Enter Phase III Clinical Trials in 2004.

Article from:
PR Newswire
Article date:
March 24, 2004
Copyright

WINCHESTER, Mass., March 24 /PRNewswire/ -- QRxPharma Pty Ltd (QRx) today announced that it has signed a development agreement with Shire Laboratories Inc., a subsidiary of Shire Pharmaceuticals Group plc , under which Shire will develop extended release formulations of QRx' novel opioid product, Q8003. Q8003, the immediate release version of the novel opioid product, is currently under development for the treatment of moderate to severe pain and is expected to be ready to enter Phase III clinical trials later this year.

"We are pleased to be working with Shire Laboratories Inc. on this exciting product opportunity," said Gary W. Pace, Ph.D., Chairman and Chief ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Rensselaer team develops novel opioid receptor ...
M2 Presswire;  January 11, 2007 ;     700+ words ... ... Rensselaer Polytechnic Institute: Rensselaer team develops novel opioid receptor compounds licensed to Alkermes, Inc.; Discovery ... Institute, has led a team in the discovery of a family of novel opioid receptor compounds that may be used in treating central nervous ...

Article: One Step Closer: Novel Opioid Receptor Compound ...
M2 Presswire;  May 8, 2009 ;     700+ words ... ... 2009-Rensselaer Polytechnic Institute: One Step Closer: Novel Opioid Receptor Compound From Rensselaer in Phase I Clinical Trials ... Institute, led a Rensselaer team in the discovery of a family of novel opioid receptor compounds with the potential to treat nervous system ...

Article: One Step Closer: Novel Opioid Receptor Compound in ...
U.S. Newswire;  May 8, 2009 ;     700+ words ... ... chemistry and chemical biology at Rensselaer Polytechnic Institute, led a Rensselaer team in the discovery of a family of novel opioid receptor compounds with the potential to treat nervous system disorders and addiction. The family of compounds was licensed ...

Article: RENSSELAER TEAM DEVELOPS NOVEL OPIOID RECEPTOR ...
US Fed News Service, Including US State News;  January 10, 2007 ;     700+ words ... ... professor of chemistry and chemical biology at Rensselaer Polytechnic Institute, has led a team in the discovery of a family of novel opioid receptor compounds that may be used in treating central nervous system disorders and addiction. The team included more than ...

Article: One Step Closer: Novel Opioid Receptor Compound in ...
Clinical Trials Week;  May 25, 2009 ;     700+ words ... ... chemistry and chemical biology at Rensselaer Polytechnic Institute, led a Rensselaer team in the discovery of a family of novel opioid receptor compounds with the potential to treat nervous system disorders and addiction. The family of compounds was licensed ...

Article: Alkermes and Rensselaer Polytechnic Institute Announce Exclusive ...
Business Wire;  October 5, 2006 ;     700+ words ... ... Polytechnic Institute today announced they have entered into a license agreement granting Alkermes exclusive rights to a family of novel opioid receptor compounds discovered at Rensselaer. These compounds represent an opportunity for Alkermes to develop important ...

Article: New Data Shows Lack of Drug Tolerance or Dependence With ...
PR Newswire;  March 15, 2002 ;     700+ words ... ... SAN FRANCISCO, Calif. -- Pain Therapeutics, Inc. , a medical research company, today presented new data on its two novel opioid painkillers, OxyTrex(TM) and MorViva(TM), at the 21st Annual Scientific Meeting of the American Pain Society in Baltimore ...

Article: Publication No. WO/2009/093917 Published on July 30, Assigned to ...
US Fed News Service, Including US State News;  August 4, 2009 ;     400 words ...GENEVA, Aug. 4 -- Andrzej Lipkowski, Poland, has developed a method of producing a novel opioid peptide. The patent has been assigned to Instytut Medycyny Doswiadczalnej I Klinicznej IM, Warszawa, Poland. According to an ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives